This reports provides a data-driven overview of the current and future competitive landscape in chronic urticaria therapeutics.
- In 2024, more than 60 million diagnosed prevalent cases of CU are anticipated in the 16 countries covered in the analyst’s epidemiology forecast for CU.
- The key players in the current CSU market include Regeneron/Sanofi with Dupixent (dupilumab) and Genentech/Novartis with Xolair (omalizumab).
- There are 42 molecules in the pipeline for CU. The Phase III pipeline consists of three drugs, followed by 17 drugs in Phase II.
- Over the past 10 years, the US has hosted the highest number of trial sites for CU, at 223 trial sites, followed by China with 186 trial sites.
- During the past decade, In Asia-Pacific, North America, and Europe, acquisition deals were more prevalent.
Scope
The Chronic urticaria: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include :
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Chronic urticaria market.
- Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Chronic urticaria market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Table of Contents2 Key Findings10 Future Market Catalysts
1 Preface
3 Disease Landscape
4 Marketed Drugs Assessment
5 Pricing and Reimbursement Assessment
6 Pipeline Drugs Assessment
7 Clinical Trials Assessment
8 Deals Landscape
9 Commercial Assessment
11 Appendix